# US 2026/0218188 A1 · Antisense oligonucleotides for rna editing and methods for using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218188 A1
- Document ID: US20260218188A1
- Status: Published application
- Kind: A1
- Application number: 19/149,086
- Filed: 2024-01-17
- Published: 2026-07-30
- Earliest claimed: 2023-01-18
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
- Inventors: Riccardo PECORI; Annette ARNOLD
- Web page: https://patentgrep.com/patent/US20260218188A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/11: Antisense
- C12N 2310/531: Stem-loop; Hairpin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention concerns antisense oligonucleotides and methods for using the same. In particular, it relates to an antisense oligonucleotide having the following elements: 3′-A1-B-A2-D-A3-5′, wherein A1 is a nucleotide sequence having a length of from 6 to 16 nucleotides; B is the nucleotide cytosine; A2 is a nucleotide sequence having a length of from 33 to 37 nucleotides; D is an internal loop-forming nucleotide sequence having a length of 4 nucleotides; and A3 is a nucleotide sequence having a length of from 10 to 20 nucleotides, wherein elements A1, A2 and A3 are contiguous nucleotide sequences that are complementary to a target nucleotide sequence, and wherein the cytosine of element B forms a base-pair mismatch with adenosine in the target nucleotide sequence upon hybridization of elements A1, A2 and A3 to the target nucleotide sequence. Furthermore, the present invention relates to an expression cassette comprising a promoter sequence driving the expression of a nucleotide encoding said antisense oligonucleotide. In addition, the present invention concerns a vector comprising a nucleic acid encoding said antisense oligonucleotide or at least said one expression cassette. The present invention further envisages use of said antisense oligonucleotide, said expression cassette or the vector for editing RNA in a cultured cell or in vitro, as well as a method for editing RNA comprising contacting the RNA to be edited in cultured cell or in vitro. Moreover, the present invention relates to a pharmaceutical composition comprising the antisense oligonucleotide, the expression cassette or the vector. Further encompassed is an antisense, an expression cassette or a vector for use in treating and/or preventing a disease or disorder associated with mutated RNA. The present invention also refers to a method for treating and/or preventing a disease associated with mutated RNA.

## Claims

### Claim 1

An antisense oligonucleotide having the following elements:
wherein
A1 is a nucleotide sequence having a length of from 6 to 16 nucleotides;
B is the nucleotide cytosine;
A2 is a nucleotide sequence having a length of from 33 to 37 nucleotides;
D is an internal loop-forming nucleotide sequence having a length of 4 nucleotides; and
A3 is a nucleotide sequence having a length of from 10 to 20 nucleotides,
wherein elements A1, A2 and A3 are contiguous nucleotide sequences that are complementary to a target nucleotide sequence, and wherein the cytosine of element B forms a base-pair mismatch with adenosine in the target nucleotide sequence upon hybridization of the elements A1, A2 and A3 to the target nucleotide sequence.

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the antisense oligonucleotide is a single-stranded antisense oligonucleotide, preferably, a single-stranded antisense RNA oligonucleotide.

### Claim 3 (depends on 1)

The antisense oligonucleotide of claim 1 having a further element E following 5′ of element A3, wherein element E is a recruitment domain for recruiting a deaminase, preferably an ADAR1 recruiting domain or an ADAR2 recruiting domain.

### Claim 4 (depends on 3)

The antisense oligonucleotide of claim 3, wherein the recruitment domain is capable of forming a stem loop structure and has a nucleotide sequence as shown in SEQ ID No: 1-4.

### Claim 5 (depends on 1)

The antisense oligonucleotide of claim 1 having a further element F linked to element A1 at its 3′ end or linked to element A3 at its 5′ end when element E is not present, wherein element F is a nucleotide sequence capable of forming a secondary or tertiary structure.

### Claim 6 (depends on 5)

The antisense oligonucleotide of claim 5, wherein the secondary structure is a hairpin loop or a pseudoknot structure and has a nucleotide sequence as shown in any one of SEQ ID Nos: 5 to 8.

### Claim 7 (depends on 1)

An expression cassette comprising a promoter sequence driving the expression of a nucleic acid encoding the antisense oligonucleotide of claim 1.

### Claim 8 (depends on 7)

The expression cassette of claim 7, wherein the promoter sequence is selected from the group consisting of: hU6-, H1-, and h7SK-promoter.

### Claim 9 (depends on 7)

The expression cassette of claim 7, wherein the expression cassette further comprises a polyU terminator.

### Claim 10 (depends on 1)

A vector comprising a nucleic acid encoding the antisense oligonucleotide of claim 1 or at least one expression cassette comprising a promoter sequence driving the expression of a nucleic acid encoding the antisense oligonucleotide of claim 1.

### Claim 11 (depends on 1)

A vector comprising at least two expression cassettes, wherein the expression cassettes each comprise a promoter sequence driving the expression of a nucleic acid encoding the antisense oligonucleotide of claim 1, and wherein the expression control sequences in at least two of the expression cassettes differ from each other.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method for editing RNA comprising contacting the RNA to be edited in cultured cell or in vitro with the antisense oligonucleotide of claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the antisense oligonucleotide of claim 1.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method for treating and/or preventing a disease associated with mutated RNA, preferably cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the antisense oligonucleotide of claim 1.
